bioAffinity Technologies Inc BIAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
-
Q2 Virtual Investor Summit Presentations Now Available On Demand
-
Q2 Investor Summit Virtual Live Wednesday June 24
-
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
-
bioAffinity Technologies Announces Closing of $3.2 Million Offering
-
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
-
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
-
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
Trading Information
- Previous Close Price
- $0.71
- Day Range
- $0.69–0.72
- 52-Week Range
- $0.61–13.50
- Bid/Ask
- $0.70 / $0.71
- Shares Outstanding
- 6.28M
- Market Cap
- $4.42M
- Volume/Avg
- 75,105 / 420,660
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.34
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 57
- Website
- https://www.bioaffinitytech.com
Valuation
|
Metric
|
BIAF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.86 |
Price/Sales | 0.34 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIAF
|
|---|---|
Quick Ratio | 1.19 |
Current Ratio | 1.36 |
Interest Coverage | −363.09 |
Quick Ratio
BIAF
Profitability
|
Metric
|
BIAF
|
|---|---|
Return on Assets (Normalized) | −191.36% |
Return on Equity (Normalized) | −407.33% |
Return on Invested Capital (Normalized) | −319.81% |
Return on Assets
BIAF
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|?R?ZD!xT | LOCK|yf< | $198B | |||
| Danaher Corp
DHR
| LOCK|?y$^^Q#X | LOCK|%^ | $144B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|x!d>z^M | LOCK|wlp | $45B | |||
| Agilent Technologies Inc
A
| LOCK|bjV<!#% | LOCK|@w | $37B | |||
| Waters Corp
WAT
| LOCK|D&%NZd$ | LOCK|>$ | $36B | |||
| IQVIA Holdings Inc
IQV
| LOCK|B!v^J&k | LOCK|K#$q | $34B | |||
| Illumina Inc
ILMN
| LOCK|G^^#GwG | LOCK|Yf?z% | $28B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|SKDnChN | LOCK|Ndvry | $26B | |||
| Quest Diagnostics Inc
DGX
| LOCK|!?!T@! | LOCK|#Zp? | $23B | |||
| Labcorp Holdings Inc
LH
| LOCK|fK^PXpp? | LOCK|dts^& | $23B |
United States